Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026 (opens original article in a new tab)

Definium Therapeutics will present topline results from its Phase 3 Emerge study on June 22, 2026, evaluating DT120 ODT for major depressive disorder.

• Definium Therapeutics will host a webcast on June 22, 2026, to discuss topline results from its Phase 3 Emerge study for DT120 ODT in major depressive disorder.
• The Emerge study is a randomized, double-blind, placebo-controlled trial with 149 participants, evaluating a single 100 µg dose of DT120 ODT versus placebo.
• The study's primary endpoint is change from baseline in MADRS total score at Week 6, with key secondary endpoints including CGI-S scores at multiple time points.